Dark

MBRX
Moleculin Biotech, Inc.
stock NASDAQ

Market Open

Jul 29, 2026 11:55:52 AM EDT

1.36USD-38.409%(-0.84)1,082,776

1.34Bid 1.37Ask 0.03Spread

Pre-market

Jul 27, 2026 9:15:30 AM EDT

2.07USD-2.387%(-0.05)0

After-hours

Jul 28, 2026 4:11:30 PM EDT

2.20USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 20, 2022

08:40AM EST Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks PR Newswire

Jan 18, 2022

08:14AM EST Moleculin Announces Updated Preliminary Safety Data For Annamycin In Its 3 Phase 1 Clinical Trials For Acute Myeloid Leukemia And Metastases Of Soft Tissue Sarcoma Benzinga

08:06AM EST Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma PR Newswire

Jan 7, 2022

08:30AM EST Moleculin to Present at the H.C. Wainwright BioConnect Conference PR Newswire

Dec 27, 2021

08:38AM EST Moleculin Biotech Inc. (MBRX) said preliminary interim results from its U.S. Phase 1b/2 clinical trial concluded the safety review of the third cohort and opens the fourth cohort in a dose escalation trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases. RTTNews

08:10AM EST Moleculin Announces Preliminary Third Cohort Interim Data In Phase 1b/2 Clinical Trial Of Annamycin For The Treatment Of Soft Tissue Sarcoma Lung Metastases Benzinga

08:09AM EST Moleculin Reports 3rd Cohort Data In Phase 1b/2 Trial Of Annamycin For Soft Tissue Sarcoma Lung Metastases Treatment RTTNews

08:05AM EST Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases PR Newswire

Dec 1, 2021

02:08PM EST Read Why Is Roth Capital Bullish On This Cancer-Focused Stock Benzinga

08:49AM EST Moleculin Biotech, Inc. (MBRX) said the FDA is allowing its Investigational New Drug application to study WP1122 for the treatment of Glioblastoma Multiforme to go forward. The company plans to begin a phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1122 in adult patients with GBM. RTTNews

08:38AM EST Moleculin Gets FDA Allowance To Begin A Phase 1 Study Of WP1122 For Treatment Of Glioblastoma Multiforme; Stock Up RTTNews

08:36AM EST Moleculin Biotech Reports Received FDA Allowance To Begin Phase 1 Study Of WP1122 For Treatment Of Glioblastoma Multiforme Benzinga

08:35AM EST Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the PR Newswire

Nov 12, 2021

08:05AM EST Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event PR Newswire

Nov 11, 2021

08:10AM EST Moleculin Biotech Q3 Loss/shr $0.15 Vs. Loss/shr $0.33 Prior Year RTTNews

08:09AM EST Moleculin Biotech Q3 EPS $(0.15) Up From $(0.36) YoY Benzinga

08:05AM EST Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs PR Newswire

Oct 19, 2021

09:16AM EDT Moleculin Gets Authorization From UK's MHRA To Commence Phase 1a Trial Of WP1122 For Treatment Of COVID-19 RTTNews

09:09AM EDT Moleculin Receives Authorization From Medicines And Healthcare Products Regulatory Agency (MHRA) To Commence Phase 1a Clinical Trial Of WP1122 For The Treatment Of COVID-19 Benzinga

09:05AM EDT Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 PR Newswire

Oct 18, 2021

08:27AM EDT Moleculin Announces Interim Data In Phase 1b/2 Clinical Trial Of Annamycin For Soft Tissue Sarcoma Lung Metastases RTTNews

08:27AM EDT Moleculin Announces Interim Data In Phase 1b/2 Clinical Trial Of Annamycin Fore Treatment Of Soft Tissue Sarcoma Lung Metastases Demonstrating 80% Clinical Activity Benzinga

08:25AM EDT Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for PR Newswire

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Sep 27, 2021

07:14AM EDT Moleculin To Present At 2021 Cantor Virtual Global Healthcare Conference Sept. 27 At 8:40 a.m. ET Benzinga

07:05AM EDT Moleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference PR Newswire

Sep 17, 2021

08:08AM EDT Moleculin Biotech To Present At Oppenheimer Fall Healthcare Life Sciences, MedTech Summit Sept. 20 At 4:35 p.m. EDT Benzinga

08:05AM EDT Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and PR Newswire

Sep 8, 2021

08:02AM EDT Moleculin to Present at the H.C. Wainwright 23rd Annual Global Investment PR Newswire

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

08:34AM EDT Moleculin Biotech Q2 EPS $(0.15) Beats $(0.19) Estimate Benzinga

08:19AM EDT Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs PR Newswire

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 13, 2021

08:38AM EDT Moleculin Receives Approval To Extend Dose Escalation In Phase 1/2 European Trial Evaluating Annamycin For AML RTTNews

08:36AM EDT Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia PR Newswire

08:36AM EDT Moleculin Receives Approval To Extend Dose Escalation In Phase 1/2 European Clinical Trial Evaluating Annamycin For Treatment Of Acute Myeloid Leukemia Benzinga

Jun 21, 2021

05:22PM EDT Moleculin Biotech 8-K Shows Co. Entered Amendment To Patent, Technology License Deal With University Of Texas Benzinga

09:08AM EDT Moleculin Biotech Commences Enrollment And Doses First Subject In Its U.S. Phase 1b/2 Clinical Trial On Annamycin RTTNews

08:39AM EDT Moleculin Biotech Reports First Subject Enrolled, Dosed In Phase 1b/2 Trial Of Annamycin For Treatment Of Sarcoma Lung Metastases Benzinga

08:35AM EDT Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical PR Newswire

Jun 15, 2021

09:08AM EDT Moleculin Announces Inclusion In Russell 2000 Index Benzinga

09:05AM EDT Moleculin Announces Inclusion in the Russell 2000(r) Index PR Newswire

May 28, 2021

04:44PM EDT Moleculin Biotech S-3 Filing Shows Registration For $200M Mixed Securities Shelf Offering Benzinga

May 25, 2021

11:24AM EDT Moleculin Biotech to Start Testing Annamycin in Sarcoma Lung Metastases Patients Benzinga

09:08AM EDT Moleculin Gets Clearance To Begin Phase 1b/2 Clinical Trial Evaluating Annamycin For Treatment Of STS Lung Metastases RTTNews

09:05AM EDT Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of PR Newswire

09:05AM EDT Moleculin Biotech Receives Clearance To Initiate Phase 1b/2 Trial Of Annamycin Benzinga

May 14, 2021

07:37AM EDT Moleculin Biotech Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases Posted to Clinical Trials Website; Study is Not Yet Recruiting Benzinga

May 12, 2021

07:41AM EDT Moleculin Biotech Q1 EPS $(0.20) Down From $(0.15) YoY Benzinga

07:38AM EDT Moleculin Biotech Q1 Net Loss $4.4 Mln Vs. Net Loss $1.2 Mln Last Year RTTNews

07:35AM EDT Moleculin Reports First Quarter 2021 Financial Results and Provides Programs PR Newswire

May 11, 2021

08:05AM EDT Moleculin Biotech to Present at the Q2 Virtual Investor Summit PR Newswire

Apr 22, 2021

08:09AM EDT The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs Benzinga

Apr 14, 2021

09:38AM EDT Moleculin Biotech Stock Is Trading Higher After WP1066 Scores Rare Pediatric Disease Tag For Type Of Brain Tumor Benzinga

07:39AM EDT Moleculin Bags New Rare Pediatric Disease Designation From FDA For WP1066 For Treatment Of Ependymoma RTTNews

07:36AM EDT Moleculin Awarded New Rare Pediatric Disease Designation From US FDA For WP1066 For The Treatment Of Ependymoma Benzinga

07:35AM EDT Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for PR Newswire

Apr 6, 2021

07:33AM EDT Moleculin Biotech Announces Engagement Of IQVIA Biotech To Manage Potential Clinical Trials Of WP1122 For COVID-19 RTTNews

07:31AM EDT Moleculin Engages IQVIA To Manage Potential COVID-19 Clinical Trial Benzinga

Mar 30, 2021

09:23AM EDT Moleculin Biotech's Stock Is Trading Higher On Accelerated Review Tag For Annamycin In Connective Tissue Cancer Benzinga

07:32AM EDT Moleculin Receives FDA Approval Of Fast Track Designation For Annamycin In Sarcoma Lung Metastases RTTNews

07:31AM EDT Moleculin Receives FDA Approval Of Fast Track Designation For Annamycin In The Treatment Of Sarcoma Lung Metastases Benzinga

07:31AM EDT Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the PR Newswire

Mar 24, 2021

07:34AM EDT Moleculin Biotech 2020 Net Loss Widens To $17.4 Mln From $4.1 Mln In Prior Year RTTNews

07:33AM EDT Moleculin Biotech FY20 EPS $(1.76), Up From $(1.95) YoY Benzinga

07:31AM EDT Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December PR Newswire

Mar 9, 2021

07:30AM EST Moleculin to Participate in Four Upcoming Healthcare Conferences PR Newswire

Feb 10, 2021

04:15PM EST Moleculin Announces Full Exercise of Over-Allotment Option PR Newswire

Feb 8, 2021

07:30AM EST Moleculin Announces Grant Awarded to Polish Research Institute for Independent PR Newswire

Feb 5, 2021

07:33AM EST Moleculin Biotech Announces Preclinical Study In Animals Showing 100% Survival Achieved In Osteosarcoma Lung Metastases Animal Model Of Annamycin Drug Benzinga

Feb 3, 2021

02:54PM EST Mid-Afternoon Market Update: Dow Gains 75 Points; GW Pharmaceuticals Shares Jump On Acquisition News Benzinga

12:53PM EST Mid-Day Market Update: Crude Oil Rises Over 2%; Vaxart Shares Plummet Benzinga

11:21AM EST Mid-Morning Market Update: Markets Mixed; Alphabet Beats Q4 Expectations Benzinga

08:32AM EST Moleculin Prices 14,273,684 Share Common Stock Offering At $4.75/Share Benzinga

08:30AM EST Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering PR Newswire

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

Feb 2, 2021

04:23PM EST Moleculin Announces Proposed Underwritten Public Offering PR Newswire

04:22PM EST Moleculin Announces Proposed Underwritten Public Offering; No Terms Disclosed Benzinga

02:54PM EST Mid-Afternoon Market Update: Dow Jumps 580 Points; Cassava Sciences Shares Spike Higher Benzinga

12:31PM EST Mid-Day Market Update: Crude Oil Rises 3%; Immunovant Shares Plummet Benzinga

11:11AM EST Mid-Morning Market Update: Markets Open Higher; Pfizer Reports Mixed Q4 Results Benzinga

10:06AM EST Shares of Moleculin Biotech, Inc. (MBRX) are surging nearly 70% on Tuesday morning after the biotechnology company announced that a pre-clinical study of treatment for osteosarcoma lung metastases achieved 100% survival rate. RTTNews

07:36AM EST Moleculin Announces 100% Survival Achieved In Osteosarcoma Lung Metastases Animal Model Benzinga

07:30AM EST Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases PR Newswire

Feb 1, 2021

07:36AM EST Moleculin Signs Agreement With Catalyst Clinical Research To Begin Sarcoma Trial Benzinga

Jan 29, 2021

09:18AM EST Moleculin Announces Reverse Stock Split PR Newswire

09:18AM EST Moleculin Biotech To Effect 1-for-6 Reverse Stock Split Of Its Common Stock RTTNews

09:18AM EST Moleculin Biotech Reports 1-For-6 Reverse Stock Split, Effective After Market Close Benzinga

Jan 7, 2021

07:30AM EST Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference PR Newswire

Dec 29, 2020

07:46AM EST Moleculin Biotech, Inc., (MBRX), a clinical stage pharmaceutical company, said Tuesday that the U.S. Food and Drug Administration or FDA has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas. The company's shares are rising more than 8 percent in pre-market activity. RTTNews

07:33AM EST Moleculin Says Annamycin Receives FDA Orphan Drug Designation For Soft Tissue Sarcomas; Stock Surges RTTNews

07:32AM EST Moleculin Biotech Shares Spike As Co. PR Highlights Monday News Of FDA Orphan Drug Designation for Soft Tissue Sarcomas Benzinga

07:30AM EST Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft PR Newswire

Dec 28, 2020

09:50AM EST Moleculin Biotech Receives FDA Orphan Drug Designation for liposomal annamycin for Treatment of soft tissue sarcomas Benzinga

Dec 17, 2020

07:43AM EST Moleculin: FDA Allowing IND Application To Study Annamycin For Soft Tissue Sarcoma Lung Metastases To Go Into Effect RTTNews

07:33AM EST Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases Benzinga

07:30AM EST Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for PR Newswire

Dec 3, 2020

07:30AM EST Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C PR Newswire

Dec 1, 2020

02:32PM EST Mid-Afternoon Market Update: Gold Rises 2%; Tuniu Shares Drop After Q3 Results Benzinga

12:33PM EST Mid-Day Market Update: Crude Oil Down Over 1%; BlackBerry Shares Jump On Amazon Partnership Benzinga

07:37AM EST Moleculin Biotech Says FDA Approved Its Request For A "Rare Pediatric Disease" Designation For WP1066 RTTNews

07:32AM EST Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations For WP1066 Benzinga

07:30AM EST Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for PR Newswire

Nov 19, 2020

07:37AM EST Moleculin Says New Data Shows Synergistic Antitumor Activity Of Annamycin Combination With Ara-C In AML RTTNews

07:32AM EST Moleculin To Present Data At American Society For Hematology Annual Conference Benzinga

07:30AM EST Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of PR Newswire

Nov 13, 2020

07:34AM EST Moleculin Biotech Late Thursday Reported Q3 EPS $(0.06) Up From $(0.09) YoY Benzinga

07:34AM EST Moleculin Biotech Q3 Loss Per Share $0.06 Vs Loss $0.09 Last Year RTTNews

07:30AM EST Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended PR Newswire

Oct 29, 2020

07:56AM EDT Moleculin Biotech Enters Agreement With University Of Campinas In So Paulo, Brazil To 'further enable collaboration into its research on the anti-viral capabilities of its drug candidate WP1122, specifically for the coronavirus.' Benzinga

07:46AM EDT Moleculin Unveils Addl. Collaboration On Drug Candidate Targeting COVID-19 RTTNews

07:30AM EDT Moleculin Announces Additional Collaboration on Drug Candidate Targeting PR Newswire

Oct 27, 2020

07:53AM EDT Moleculin To Participate In Panel At ROTH Capital's 'COVID-19 Therapeutics in Development' Healthcare Event Oct. 28 12:00-1:20 pm ET Benzinga

07:30AM EDT Moleculin to Participate in Panel at ROTH Capital's "COVID-19 Therapeutics in PR Newswire

Oct 21, 2020

07:41AM EDT Moleculin Biotech Reports Independent Lab Results Validating Internal Animal Studies Showing Ability Of Annamycin To Target Lung Localized Tumors Benzinga

07:30AM EDT Moleculin Announces Independent Study Validates Annamycin's Ability to Target PR Newswire

Oct 13, 2020

07:32AM EDT Moleculin Announces Additional Positive Interim Results In Adult Glioblastoma Clinical Trial RTTNews

07:32AM EDT Moleculin Biotech Announces Additional Prelim. Data From Phase 1 Glioblastoma Clinical Trial Benzinga

07:30AM EDT Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma PR Newswire

Oct 6, 2020

07:35AM EDT Moleculin Biotech Announces New Findings In Vitro Activity Against HIV RTTNews

07:32AM EDT Moleculin Announces Its WP1096 And WP1097 Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV; Also Show Activity In Zika And Dengue Fever Benzinga

07:30AM EDT Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity PR Newswire

Oct 5, 2020

07:36AM EDT Moleculin Biotech Appoints Elizabeth Cermak To Board RTTNews

07:30AM EDT Moleculin Appoints Elizabeth Cermak to Board of Directors PR Newswire

Oct 1, 2020

07:42AM EDT Moleculin Announces Positive Interim Results In Pediatric Brain Tumor Phase 1 Trial At Emory University RTTNews

07:35AM EDT Moleculin Biotech Reports Interim Results In Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University: WP1066 Showed Activity In Diffuse Intrinsic Pontine Glioma Benzinga

07:33AM EDT Moleculin Announces Positive Interim Results In Pediatric Brain Tumor Phase 1 Clinical Trial At Emory University Benzinga

07:30AM EDT Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 PR Newswire

Sep 29, 2020

03:33PM EDT Moleculin shares are trading higher after the company announced it has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2. Benzinga

08:00AM EDT Moleculin Announces Discovery Of Significant In Vitro Activity Against COVID-19 Virus For New Antimetabolites RTTNews

07:30AM EDT Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 PR Newswire

Sep 14, 2020

08:53AM EDT Moleculin Biotech Inc. (MBRX) said Monday that it has contracted with an independent laboratory to test the antiviral activity of its WP1122 portfolio in a COVID-19 animal model. RTTNews

07:39AM EDT Moleculin Biotech To Test Antiviral Activity Of WP1122 In COVID-19 Animal Model RTTNews

07:32AM EDT UPDATE: Moleculin Says Contracted With An Independent Laboratory To Test The Antiviral Activity Of Its WP1122 Portfolio In A Covid-19 Animal Model Benzinga

07:31AM EDT Moleculin Announces COVID-19 In Vivo Testing Contracted For WP1122 Benzinga

Sep 9, 2020

01:53PM EDT BRK Extends its Footprint into Europe and CIS and "EV" Vehicles with Key PR Newswire

07:36AM EDT Moleculin Biotech Intends To File IND Using Annamycin For Soft Tissue Sarcomas With Lung Metastases By Year-End RTTNews

07:32AM EDT Moleculin Announces Successful Completion Of Pre-IND Meeting With FDA Benzinga

Aug 27, 2020

07:30AM EDT Moleculin to Present at LD Micro 500 Virtual Investor Conference PR Newswire

Aug 12, 2020

07:44AM EDT Moleculin Biotech Q2 Net Loss $10.1 Mln Vs. Net Loss Of $1.2 Mln Prior Year RTTNews

07:40AM EDT Moleculin Biotech Q2 EPS $(0.17) Down From $(0.03) YoY Benzinga

07:30AM EDT Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June PR Newswire

Jul 29, 2020

07:39AM EDT Moleculin Biotech Highlights Publication At University of Campinas Demonstrating 'RS-CoV-2 infection is supported by elevated glucose levels and that inhibition of glycolysis with 2-deoxy-D-glucose ("2-DG") effectively eliminated viral load in vitro' Benzinga

07:30AM EDT Additional Independent Research Further Supports Glucose Metabolism as PR Newswire

Jul 21, 2020

09:14AM EDT Moleculin Biotech, Inc., (MBRX), a clinical stage pharmaceutical company, said Tuesday that a second round of independent laboratory testing has confirmed the antiviral activity of its drug candidate WP1122, against coronavirus. RTTNews

07:36AM EDT Moleculin Biotech Says New Independent Laboratory Testing Confirms Antiviral Activity Of WP1122 Against Coronavirus RTTNews

07:33AM EDT Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity Of WP1122 In Coronavirus Benzinga

07:30AM EDT Moleculin Announces New Independent In Vitro Testing Confirms Antiviral PR Newswire

Jul 15, 2020

02:43PM EDT Mid-Afternoon Market Update: Dow Surges Over 200 Points; Moleculin Biotech Shares Climb Benzinga

08:53AM EDT Shares of Moleculin Biotech Inc. (MBRX) are suring over 38% in pre-market today, following the company's agreement with Sterling Pharma USA LLC for US production of WP1122 to support its expanded development efforts in preparation for submitting the FDA request for Investigational New Drug or IND status for WP1122 for the potential treatment of COVID-19. RTTNews

07:34AM EDT Moleculin Biotech Enters Deal With Sterling Pharma USA LLC For US Production Of WP1122 RTTNews

07:31AM EDT Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate Benzinga

07:30AM EDT Moleculin Announces Agreement to Produce WP1122 for Expanded Development of PR Newswire